



Xopenex HFA[®] (levalbuterol tartrate) – First-Time Generic

- On October 3, 2016, [Teva launched](#) an authorized generic version of Sunovion's [Xopenex HFA \(levalbuterol tartrate\)](#) 45 mcg/actuation inhalation aerosol.
- Xopenex HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.
- [Xopenex](#) is also available generically as an inhalation solution in the following strengths: 0.31 mg/3 mL, 0.63 mg/3 mL, and 1.25 mg/3 mL and as concentrate inhalation solution, 1.25 mg/0.5 mL.
 - Xopenex concentrate and inhalation solution have the same indication as Xopenex HFA, except both the concentrate and inhalation solution are indicated in children 6 years of age and older.
- The wholesale acquisition cost (WAC) for Teva's generic Xopenex HFA is \$58.96 per 15 g or 200 actuations.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News[®] is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.